SABS — SAB Biotherapeutics Balance Sheet
0.000.00%
- $16.63m
- -$0.44m
- $1.32m
Annual balance sheet for SAB Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 12.6 | 33.2 | 15 | 56.6 | 20.8 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20.6 | 8.01 | 5.56 | 0 | 0.055 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 34.5 | 50.2 | 22.1 | 58.9 | 23.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 22.1 | 30.9 | 28.3 | 24.7 | 19.9 |
Other Long Term Assets | |||||
Total Assets | 56.5 | 81.1 | 50.9 | 83.9 | 44.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.1 | 26.5 | 15 | 10.8 | 7.98 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 17.5 | 42.6 | 19.8 | 26.6 | 18.2 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 39 | 38.5 | 31.1 | 57.3 | 26 |
Total Liabilities & Shareholders' Equity | 56.5 | 81.1 | 50.9 | 83.9 | 44.2 |
Total Common Shares Outstanding |